Clinical Trial Update: Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-weekly versus twice-weekly carfilzomib plus dexamethasone in adults with relapsed/refractory multiple myeloma completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2018-12-13